These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 38083865

  • 1. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
    Tefferi A, Fleti F, Chan O, Al Ali NH, Al-Kali A, Begna KH, Foran JM, Badar T, Khera N, Shah M, Hiwase D, Padron E, Sallman DA, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R.
    Br J Haematol; 2024 Apr; 204(4):1243-1248. PubMed ID: 38083865
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
    Deng J, Wu X, Ling Y, Liu X, Zheng X, Ye W, Gong Y.
    Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
    [Abstract] [Full Text] [Related]

  • 9. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S, Kohlmann A, Schnittger S, Kern W, Haferlach T, Haferlach C.
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E.
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [Abstract] [Full Text] [Related]

  • 12. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.
    McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF.
    Blood Cancer J; 2015 Mar 13; 5(3):e291. PubMed ID: 25768405
    [Abstract] [Full Text] [Related]

  • 13. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
    Smith AE, Kulasekararaj AG, Jiang J, Mian S, Mohamedali A, Gaken J, Ireland R, Czepulkowski B, Best S, Mufti GJ.
    Lancet Haematol; 2015 May 13; 2(5):e212-21. PubMed ID: 26688096
    [Abstract] [Full Text] [Related]

  • 14. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
    Stengel A, Kern W, Haferlach T, Meggendorfer M, Haferlach C.
    Genes Chromosomes Cancer; 2016 Oct 13; 55(10):777-85. PubMed ID: 27218649
    [Abstract] [Full Text] [Related]

  • 15. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
    Fernandez-Mercado M, Burns A, Pellagatti A, Giagounidis A, Germing U, Agirre X, Prosper F, Aul C, Killick S, Wainscoat JS, Schuh A, Boultwood J.
    Haematologica; 2013 Dec 13; 98(12):1856-64. PubMed ID: 23831921
    [Abstract] [Full Text] [Related]

  • 16. Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
    Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, Jädersten M, Grandien A, Douagi I, Neuberg DS, LeBlanc K, Boultwood J, Karimi M, Jacobsen SE, Woll PS, Hellström-Lindberg E.
    Haematologica; 2017 Mar 13; 102(3):498-508. PubMed ID: 27884971
    [Abstract] [Full Text] [Related]

  • 17. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.
    Talati C, Sallman D, List AF.
    Clin Lymphoma Myeloma Leuk; 2018 Oct 13; 18(10):629-635. PubMed ID: 30097406
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.
    Jiang L, Ye L, Ma L, Ren Y, Zhou X, Mei C, Xu G, Yang H, Lu C, Luo Y, Zhu S, Wang L, Shen C, Yang W, Zhang Q, Wang Y, Lang W, Han Y, Jin J, Tong H.
    J Cancer Res Clin Oncol; 2022 Apr 13; 148(4):845-856. PubMed ID: 35013795
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.
    Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti GJ, Robin M, Kröger N.
    Biol Blood Marrow Transplant; 2018 Mar 13; 24(3):507-513. PubMed ID: 29196078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.